ProTAME consistently downregulated MMP2 expression in bladder cancer cells, also exhibiting notable downregulatory effects when used in combination with other agents, which may be linked to the ability of proTAME to block APC/C activation by CDC20 and CDH1, thus interfering with pathways involved in cell cycle progression and protease production [13]. The gene discussed is MMP2; the disease is urinary bladder cancer.